Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday. CEO Albert Bourla also said the company has been in active discussions with members of the U.

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pfizer increased its 2025 profit outlook by 10 cents a share to a range of $2.90 a share to $3.10 a share, citing continued cost cuts, a lower tax rate and “confidence” that strength seen in the first half of the year will continue.